Fig. 5: Cal27-derived EVs secretion is reduced in CHMP2A-KO cells and in tipifarnib treated WT Cal27 cells.

a, b Charts showing the size distribution and number of EVs secreted from Cal27-WT (a) and KO (b) cells. Samples were loaded on a Nanosight LM10 and analyzed for 1 min for each of n = 5 technical replicates and the error bars represent ±SEM across n = 5. c comparison of EV number in Cal27-WT and KO calculated on 10 μl of EV suspension diluted in 1 ml of DPBS. d average EVs size analyzed during nanoparticle tracking of Cal27-WT and KO derived EVs. e comparison of EVs number in Cal27-WT treated with tipifarnib (Tip) and the corresponding DMSO control (CTRL) calculated on 10 μl of EVs suspension diluted in 1 ml of DPBS. c–e error bars represent ±SEM across n = 5 technical replicates and unpaired two-tailed Student’s t test was performed to determine statistically. f 4 hour cytotoxicity assay using NK cells as effectors against Cal27-WT, KO treated with tipifarnib or DMSO (CTRL). Error bars represent ±SEM, n = 3 replicates. Statistical analysis was performed by two-way ANOVA and Bonferroni’s post hoc multiple comparison test (comparing Cal27-WT vs Cal27-WT + Tip E:T, 10:1 p < 0.0001; 5:1 p < 0.0001; 2:1 and 1:1 ns). Data are shown in a–f, representative of n = 3 independent experiments.